The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

[1] Bray GA(2017)Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation Obes Rev 18 715-723

[2] Kim KK(2014)Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 384 766-781

[3] Wilding JPH(2022)Changes in the use of glucose-lowering drugs: a Danish nationwide study Diabetes Obes Metab 23 40-52

[4] Ng M(2021)Understanding the place for GLP-1RA therapy: translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection Diabetes Obes Metab 385 503-515

[5] Fleming T(2021)Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes N Engl J Med 5 209ra151-62

[6] Robinson M(2013)Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Sci Transl Med 24 51-801

[7] Pottegård A(2016)Unimolecular polypharmacy for treatment of diabetes and obesity Cell Metab 133 e167952-2817.e28

[8] Andersen JH(2023)Dual gut hormone receptor agonists for diabetes and obesity J Clin Invest 71 793-2475

[9] Søndergaard J(2019)The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis J Hepatol 20 2809-756

[10] Thomsen RW(2022)2019 global NAFLD prevalence: a systematic review and meta-analysis Clin Gastroenterol Hepatol 70 2468-837

[1] Bray GA(2017)Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation Obes Rev 18 715-723

[2] Kim KK(2014)Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 384 766-781

[3] Wilding JPH(2022)Changes in the use of glucose-lowering drugs: a Danish nationwide study Diabetes Obes Metab 23 40-52

[4] Ng M(2021)Understanding the place for GLP-1RA therapy: translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection Diabetes Obes Metab 385 503-515

[5] Fleming T(2021)Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes N Engl J Med 5 209ra151-62

[6] Robinson M(2013)Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Sci Transl Med 24 51-801

[7] Pottegård A(2016)Unimolecular polypharmacy for treatment of diabetes and obesity Cell Metab 133 e167952-2817.e28

[8] Andersen JH(2023)Dual gut hormone receptor agonists for diabetes and obesity J Clin Invest 71 793-2475

[9] Søndergaard J(2019)The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis J Hepatol 20 2809-756

[10] Thomsen RW(2022)2019 global NAFLD prevalence: a systematic review and meta-analysis Clin Gastroenterol Hepatol 70 2468-837